
    
      This is an open-label, parallel group study where eligible elderly adults (aged 65-85 years
      inclusive) and younger adults (aged 18-55 years inclusive) and who are matched to the elderly
      participants by sex and body mass index (BMI) (Â± 10%) will receive a single dose of 30 mg
      apremilast under fasting conditions.
    
  